Cargando…
Potential Drug-Drug Interactions among Patients with Schizophrenia Spectrum Disorders: Prevalence, Association with Risk Factors, and Replicate Analysis in 2021
Background and Objectives: Patients with schizophrenia are often exposed to polypharmacotherapy, which may lead to drug—drug interactions. The aim of the study was to investigate the prevalence of potential drug—drug interactions (pDDIs) in hospitalized patients with schizophrenia spectrum disorders...
Autores principales: | Bačar Bole, Cvetka, Nagode, Katja, Pišlar, Mitja, Mrhar, Aleš, Grabnar, Iztok, Vovk, Tomaž |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962414/ https://www.ncbi.nlm.nih.gov/pubmed/36837485 http://dx.doi.org/10.3390/medicina59020284 |
Ejemplares similares
-
Febrile neutropenia in chemotherapy treated small-cell lung cancer patients
por: Kukec, Renata Rezonja, et al.
Publicado: (2015) -
The Role of Reactive Species in Epileptogenesis and Influence of Antiepileptic Drug Therapy on Oxidative Stress
por: Martinc, Boštjan, et al.
Publicado: (2012) -
Oxidative Stress in Schizophrenia
por: Bošković, Marija, et al.
Publicado: (2011) -
The Evolving Role of Microsampling in Therapeutic Drug Monitoring of Monoclonal Antibodies in Inflammatory Diseases
por: Mingas, Panagiotis-Dimitrios, et al.
Publicado: (2021) -
Curriculum Mapping of the Master’s Program in Pharmacy in Slovenia with the PHAR-QA Competency Framework
por: Gmeiner, Tanja, et al.
Publicado: (2017)